Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) selected the 200-mcg dose of its SkinJect patch for further development after completing a Phase 2 basal cell carcinoma study, supporting the …
ISYMI: Medicus Picks 200-Mcg SkinJect Dose for Gorlin Program Read More
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) received U.S. Food and Drug Administration clearance to begin a Phase 1 trial of PRT13722, moving its experimental KAT6A-targeting breast cancer drug …
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has dosed the first patient in a Phase 1 trial of CT-202, moving its Nectin-4 x CD3 bispecific antibody into human testing …
Context Therapeutics Starts Phase 1 Trial of CT-202 Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) is using clinical data from an investigator-led study to support trans-radial use of its Dynetic-35 stent for treating iliac artery lesions, offering physicians …
Teleflex Study Backs Radial Access for Iliac Stenting Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has dosed the first patient in a global Phase 3 trial of OCU410, moving its one-time gene therapy for geographic atrophy into pivotal …
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts and passed an interim statistical review …
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills Read More
PHOENIXVILLE, PA — PleoPharma Inc. secured a $6.5 million federal grant to advance a Phase 3 trial of its experimental treatment for cannabis withdrawal symptoms, providing three years of funding …
PleoPharma Wins $6.5 Million NIH Grant for Phase 3 Trial Read More
WASHINGTON, D.C. — The U.S. Department of Veterans Affairs is launching a randomized clinical trial of psilocybin for veterans with treatment-resistant major depressive disorder, including participants with concurrent post-traumatic stress …
VA Launches Psilocybin Trial for Treatment-Resistant Depression Read More
KING OF PRUSSIA, PA — CSL plans to seek approval to expand ANDEMBRY to children ages 2 through 11 after a Phase 3b study found most participants remained free of …
CSL Plans Pediatric ANDEMBRY Filing After Phase 3b Data Read More MALVERN, PA — The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Ocugen Inc.’s experimental OCU410 gene therapy for geographic atrophy, giving the blindness treatment access …
FDA Gives Ocugen Gene Therapy Expedited Regulatory Status Read More